International Journal of Drug Delivery Technology
Volume 14, Issue 3

Aptamer Insights in Targeting and Designing of Therapeutic Drugs

Mishra A*, Abdullah SM, Koley S, Modak S, Das A

Jharkhand Rai University, Rajaulatu Campus, Namkum, Ranchi, Jharkhand, India

Received: 07th March, 2024; Revised: 04th May, 2024; Accepted: 15thJuly, 2024; Available Online: 25th September, 2024 

ABSTRACT

In the therapy of chronic and dangerous conditions like as cancer, heart disease, neurological illnesses, or retinal angiopathy, we frequently require most effective dosage schedule with adequate precision and sufficient therapeutic potential. Among these entities with the capacity to behave in a target-specific way are aptamers. Usually, they are produced by an iterative screening procedure named “Systemic Evolution of Ligands by Exponential Enrichment (SELEX)” which is used to complicate nucleic acid libraries. For several biological purposes, including targeted treatment, aptamers are potential and could be easily molded into desirable needs and also be tested in a manner that is not very extravagant or pricey. Chemical modification can be employed to enhance their pharmacological actions or prevent enzymatic degradation, hence guaranteeing their chemical integrity and bioavailability in a physiological setting. The recent advancements made in drug targeting and design with the use of aptamers are the main topic of this review. This review will highlight current developments and go over prospects and problems in the fields of aptamer-based targeted therapy, including aptamer therapeutics.

Keywords: Aptamer, SELEX, Targeted therapy, Drug discovery, Chronic disease. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.81

How to cite this article: Mishra A, Abdullah SM, Koley S, Modak S, Das A. Aptamer Insights in Targeting and Designing of Therapeutic Drugs. International Journal of Drug Delivery Technology. 2024;14(3):1829-1835.

REFERENCES

  1. Yang LF, Ling M, Kacherovsky N, Pun SH. Aptamers 101: aptamer discovery and in-vitro applications in biosensors and separations. Chemical 2023. DOI: 10.1039/d3sc00439b
  2. Srivastava S, Abraham PR, Mukhopadhyay S. Aptamers: An emerging tool for diagnosis and therapeutics in tuberculosis. Frontiers in Cellular and Infection 2021, 1;11:656421. DOI: 10.3389/fcimb.2021.656421
  3. Chen F, Zhou J, Luo F, Mohammed AB, Zhang XL. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochemical and biophysical research 2007,8;357(3):743-8. DOI: 10.1016/j.bbrc.2007.04.007
  4. Baird Where are all the aptamers?. American journal of clinical pathology. 2010,1;134(4):529-31.DOI: 10.1309/ AJCPFU4CG2WGJJKS
  5. Lorsch JR, Szostak JW. In-vitro selection of RNA aptamers specific for Biochemistry. 1994,1;33(4):973-82. DOI:10.1021/bi00170a016
  6. Ali MH, Elsherbiny ME, Emara Updates on aptamer research. International journal of molecular sciences. 2019,21;20(10):2511. DOI:10.3390/ijms20102511
  7. Stoltenburg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer Analytical and bioanalytical chemistry. 2005,383;83-91. DOI: 10.1007/ s00216-005-3388-9
  8. Pobanz K, Lupták Improving the odds: Influence of startingpools on in-vitro selection outcomes. Methods. 2016, 15;106:14-DOI: 10.1016/j.ymeth.2016.04.021
  9. Schmitz A, Weber A, Bayin M, Breuers S, Fieberg V, Famulok M, Mayer G. A SARS‐CoV‐2 spike binding DNA Aptamer that inhibits Pseudovirus infection by an RBD‐independent Angewandte Chemie International Edition. 2021,26;60(18):10279-85.DOI: 10.1002/anie.202100316
  10. Kacherovsky N, Cardle II, Cheng EL, Yu JL, Baldwin ML, Salipante SJ, Jensen MC, Pun SH. Traceless aptamer-mediated isolation of CD8+ T cells for chimeric antigen receptor T-cell therapy. Nature biomedical engineering. 2019,3(10):783-95. DOI:10.1038/s41551-019-0411-6
  11. Legiewicz M, Lozupone C, Knight RO, Yarus Size, constant sequences, and optimal selection. Rna. 2005, 1;11(11):1701-9. DOI:10.1261/rna.2161305
  12. Wang T, Chen C, Larcher LM, Barrero RA, Veedu Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. Biotechnology advances. 2019, 1;37(1):28-50. DOI: 10.1016/j. biotechadv.2018.11.001
  13. Elskens JP, Elskens JM, Madder A. Chemical modification of aptamers for increased binding affinity in diagnostic applications: Current status and future International journal of molecular sciences. 2020, 25;21(12):4522. DOI:10.3390/ ijms21124522
  14. McCloskey CM, Li Q, Yik EJ, Chim N, Ngor AK, Medina E, Grubisic I, Co Ting Keh L, Poplin R, Chaput JC. Evolution of functionally enhanced α-L-threofuranosyl nucleic acid ACS Synthetic Biology. 2021, 5;10(11):3190-9. DOI:10.1021/acssynbio.1c00481
  15. Klubmann S, Nolte A, Bald R, Erdmann VA, Fürste Mirror- image RNA that binds D-adenosine. Nature biotechnology. 1996, 1;14(9):1112-5. DOI :10.1038/nbt0996-1112
  16. Lv J, Zhen X, Li D, Liao G, Long Z, Zhang N, Liu X, Bing T, Shangguan D. Generation of an Aptamer Targeting Receptor- Type Tyrosine-Protein Phosphatase F. Analytical Chemistry. 2023 3;95(2):1228-33. DOI:10.1021/acs.analchem.2c03988
  17. Kolm C, Cervenka I, Aschl UJ, Baumann N, Jakwerth S, Krska R, Mach RL, Sommer R, DeRosa MC, Kirschner AK, Farnleitner DNA aptamers against bacterial cells can be efficiently selected by a SELEX process using state-of-the art qPCR and ultra-deep sequencing. Scientific reports. 2020, 1;10(1):20917. DOI:10.1038/s41598-020-77221-9
  18. Sefah K, Shangguan D, Xiong X, O’donoghue MB, Tan W. Development of DNA aptamers using Cell-SELEX. Nature protocols. 2010,5(6):1169-85. DOI:10.1038/nprot.2010.66
  19. Mendonsa SD, Bowser MT. In-vitro evolution of functional DNA using capillary electrophoresis. Journal of the American Chemical 2004, 14;126(1):20-1. DOI:10.1021/ja037832s
  20. Luo Z, Zhou H, Jiang H, Ou H, Li X, Zhang L. Development of a fraction collection approach in capillary electrophoresis SELEX for aptamer selection. Analyst. 2015;140(8):2664-70. DOI: 10.1039/x0xx00000x
  21. Stoltenburg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer Analytical and bioanalytical chemistry. 2005, 383:83-91. DOI:10.1007/ s00216-005-3388-9
  22. Song Y, Zhu Z, An Y, Zhang W, Zhang H, Liu D, Yu C, Duan W, Yang CJ. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell Analytical chemistry. 2013, 16;85(8):4141-9. DOI:10.1021/ac400366b
  23. Higuchi RG, Ochman H. Production of single-stranded DNA templates by exonuclease digestion following the polymerase chain Nucleic acids research. 1989 25;17(14):5865.DOI: 10.1093/nar/17.14.5865
  24. Bruno JG, Carrillo MP, Richarte AM, Phillips T, Andrews C, Lee JS. Development, screening, and analysis of DNA aptamer libraries potentially useful for diagnosis and passive immunity of arboviruses. BMC research notes. 2012;5(1):1-2. DOI:10.1186/1756-0500-5-633
  25. Gyllensten UB, Erlich Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proceedings of the National Academy of Sciences. 1988;85(20):7652-6. DOI:10.1073/ pnas.85.20.7652
  26. Williams KP, Bartel PCR product with strands of unequal length. Nucleic acids research. 1995, 10;23(20):4220. DOI:10.1093/nar/23.20.4220
  27. Bruno JG, Carrillo MP, Richarte AM, Phillips T, Andrews C, Lee JS. Development, screening, and analysis of DNA aptamer libraries potentially useful for diagnosis and passive immunity of arboviruses. BMC research notes. 2012; 5(1):1-2. DOI:10.1186/1756-0500-5-633
  28. Alam KK, Chang JL, Burke FASTAptamer: a bioinformatic toolkit for high-throughput sequence analysis of combinatorial selections. Molecular Therapy-Nucleic Acids. 2015 1;4. DOI: 10.1038/mtna.2015.4
  29. Spalluto LB, Bonnet K, Sonubi C, Ernst LL, Wahab R, Reid SA, Agrawal P, Gregory K, Davis KM, Lewis JA, Berardi E. Barriers to implementation of breast cancer risk assessment: the health care team Journal of the American College of Radiology. 2023,1;20(3):342-51. DOI: 10.1016/j.jacr.2022.12.019
  30. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, SoerjomataramCurrent and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022,1;66:15-23. DOI: 10.1016/j.breast.2022.08.010
  31. Maheshwari N, Sharma MC. Laser empowered ‘chemo- free’phytotherapy: Newer approach in anticancer therapeutics delivery. Journal of Drug Delivery Science and Technology. 2022, 22:103709.DOI: 10.1016/j.jddst.2022.103709
  32. Tekade RK, Maheshwari R, Soni N, Tekade M, Chougule MB. Nanotechnology for the development of nanomedicine. InNanotechnology-based approaches for targeting and delivery of drugs and genes 2017, 1; 3-61. Academic DOI: 10.1016/B978-0-12-809717-5.00001-4
  33. Ning Y, Hu J, Lu F. Aptamers used for biosensors and targeted therapy. Biomedicine & Pharmacotherapy. 2020,1;132:110902. DOI: 10.1016/j.biopha.2020.110902
  34. Hazeri Y, Samie A, Ramezani M, Alibolandi M, Yaghoobi E, Dehghani S, Zolfaghari R, Khatami F, Zavvar T, Nameghi MA, Abnous K. Dual-targeted delivery of doxorubicin by mesoporous silica nanoparticle coated with AS1411 aptamer and RGDK-R peptide to breast cancer in-vitro and in vivo. Journal of Drug Delivery Science and Technology. 2022, 1;71:103285. DOI:10.1016/j.jddst.2022.103285
  35. Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram Role of Fcγ receptors in HER2-targeted breast cancer therapy. Journal for immunotherapy of cancer. 2022;10(1). DOI: 10.1136/jitc-2021-003171
  36. Usui Y, Westenskow PD, Murinello S, Dorrell MI, Scheppke L, Bucher F, Sakimoto S, Paris LP, Aguilar E, FriedlanderAngiogenesis and eye disease. Annual review of vision science. 2015,24;1:155-84. DOI: 10.1146/annurev- vision-082114-035439
  37. Rossino MG, Dal Monte M, Casini G. Relationships between neurodegeneration and vascular damage in diabetic Frontiers in Neuroscience. 2019,8;13:1172. DOI: 10.3389/ fnins.2019.01172.
  38. Jadeja RN, Martin Oxidative stress and inflammation inretinal degeneration. Antioxidants. 2021, 17;10(5):790. DOI:10.3390/antiox10050790.
  39. Anguita R, Tasiopoulou A, Shahid S, Roth J, Sim SY, Patel PJ. A review of aflibercept treatment for macular disease. Ophthalmology and Therapy. 2021; 10:413-28. DOI: 10.1007/ s40123-021-00354-1.
  40. Drolet DW, Green LS, Gold L, Janjic Fit for the eye: aptamers in ocular disorders. Nucleic acid therapeutics. 2016,1;26(3):127-DOI: 10.1089/nat.2015.0573
  41. Ng EW, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature reviews drug discovery. 2006, 1;5(2):123-32.DOI: 10.1038/nrd1955
  42. Ismail SI, Alshaer W. Therapeutic aptamers in discovery, preclinical and clinical Advanced Drug Delivery Reviews. 2018, 1;134:51-64. DOI: 10.1016/j.addr.2018.08.006\
  43. Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD-Full Text View-ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/ NCT02214628?term=Fovista&phase=01&draw=2&rank=1 (accessed on JAN 2024).
  44. Jaffe GJ, Eliott D, Wells JA, Prenner JL, Papp A, Patel A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2016, 1;123(1):78-85. DOI: 10.1016/j.ophtha.2015.09.004
  45. Jia W, Yao Z, Zhao J, Guan Q, Gao L. New perspectives of physiological and pathological functions of nucleolin (NCL). Life 2017, 1;186:1-0. DOI: 10.1016/j.lfs.2017.07.025
  46. Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood. 2006,1;107(9):3564-71. DOI: 10.1182/blood-2005-07-2961
  47. Iturriaga-Goyon E, Vivanco-Rojas O, Magaña-Guerrero FS, Buentello-Volante B, Castro-Salas I, Aguayo-Flores JE, Gracia-Mora I, Rivera-Huerta M, Sánchez-Bartés F, Garfias Y. AS1411 nucleolin-specific binding aptamers reduce pathological angiogenesis through inhibition of nucleolin phosphorylation. International Journal of Molecular Sciences. 2021, 5;22(23):13150. DOI: 10.3390/ijms222313150
  48. Santos T, Miranda A, Campello MP, Paulo A, Salgado G, Cabrita EJ, Cruz Recognition of nucleolin through interaction with RNA G- quadruplex. Biochemical Pharmacology. 2021,1;189:114208. DOI: 10.1016/j.bcp.2020.114208
  49. Moreira D, Leitão D, Lopes-Nunes J, Santos T, Figueiredo J, Miranda A, Alexandre D, Tomaz C, Mergny JL, Cruz G-Quadruplex Aptamer-Ligand Characterization. Molecules. 2022,11;27(20):6781. DOI: 10.3390/molecules27206781
  50. Samarasinghe KT, Crews Targeted protein degradation: A promise for undruggable proteins. Cell chemical biology. 2021,15;28(7):934-51. DOI: 10.1016/j.chembiol.2021.04.011.
  51. Zhu G, Chen X. Aptamer-based targeted therapy. Advanced drug delivery reviews. 2018,1;134:65-78. DOI: 10.1016/j. 2018.08.005.
  52. Li R, Liu M, Yang Z, Li J, Gao Y, Tan R. Proteolysis- targeting chimeras (PROTACs) in cancer therapy: present and future. Molecules. 2022,12;27(24):8828. DOI: 10.3390/
  53. Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, Schuh M. A method for the acute and rapid degradation of endogenous Cell. 2017,14;171(7):1692- 706. DOI: 10.1016/j.cell.2017.10.033.
  54. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nature reviews Drug discovery. 2017;16(3):181-202. DOI: 1038/nrd.2016.199.
  55. Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Proteolysis- targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation. Chemical Society Reviews. 2022;51(13):5330-50. DOI: 10.1039/d1cs00762a